Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant

Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant Publisher Pubmed

Zuo F¹ ; Abolhassani H¹ ; Du L¹ ; Piralla A² ; Bertoglio F³ ; De Camposmata L¹ ; Wan H¹ ; Schubert M³ ; Cassaniti I² ; Wang Y¹ ; Sammartino JC² ; Sun R¹ ; Vlachiotis S¹ ; Bergami F² Show All Authors

Zuo F¹
Abolhassani H¹
Du L¹
Piralla A²
Bertoglio F³
De Camposmata L¹
Wan H¹
Schubert M³
Cassaniti I²
Wang Y¹
Sammartino JC²
Sun R¹
Vlachiotis S¹
Bergami F²
Kumagaibraesch M⁴
Andrell J⁵
Zhang Z⁶
Xue Y⁷
Wenzel EV^{3, 8}
Calzolai L⁹
Varani L¹⁰
Rezaei N¹¹
Chavoshzadeh Z¹²
Baldanti F^{2, 13}
Hust M³
Hammarstrom L¹
Marcotte H¹
Panhammarstrom Q¹

Show Affiliations

1. Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden
2. Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3. Department of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universitat Braunschweig, Braunschweig, Germany
4. Division of Transplantation Surgery, CLINTEC, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
5. Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden
6. Department of Aging Neurology orthopedics, Karolinska University Hospital Huddinge, Stockholm, Sweden
7. Department of Immunology, Peking University Health Science Center, Beijing, China
8. Abcalis GmbH, Science Campus Braunschweig-Sud, Inhoffenstr. 7, Braunschweig, 38124, Germany
9. European Commission, Joint Research Centre, Ispra, Italy
10. Institute for Research in Biomedicine, Universita della Svizzera italiana (USI), Bellinzona, Switzerland
11. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Childrenâ€™s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
12. Pediatric Infections Research Center, Mofid Childrenâ€™s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
13. Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy

Source: Nature Communications Published:2022

Abstract

The recent emergence of the Omicron variant has raised concerns on vaccine efficacy and the urgent need to study more efficient vaccination strategies. Here we observed that an mRNA vaccine booster in individuals vaccinated with two doses of inactivated vaccine significantly increased the plasma level of specific antibodies that bind to the receptor-binding domain (RBD) or the spike (S) ectodomain (S1 + S2) of both the G614 and the Omicron variants, compared to two doses of homologous inactivated vaccine. The level of RBD- and S-specific IgG antibodies and virus neutralization titers against variants of concern in the heterologous vaccination group were similar to that in individuals receiving three doses of homologous mRNA-vaccine or a boost of mRNA vaccine after infection, but markedly higher than that in individuals receiving three doses of a homologous inactivated vaccine. This heterologous vaccination regime furthermore significantly enhanced the RBD-specific memory B cell response and S1-specific T cell response, compared to two or three doses of homologous inactivated vaccine. Our study demonstrates that mRNA vaccine booster in individuals vaccinated with inactivated vaccines can be highly beneficial, as it markedly increases the humoral and cellular immune responses against the virus, including the Omicron variant. © 2022, The Author(s).

2. Omicron Variant of Covid-19: A Focused Review of Biologic, Clinical, and Epidemiological Changes, Immunopathologia Persa (2023)

3. Oral Antiviral Treatments for Covid-19: Opportunities and Challenges, Pharmacological Reports (2022)

4. Efficacy of Mrna, Adenoviral Vector, and Perfusion Protein Covid-19 Vaccines, Biomedicine and Pharmacotherapy (2022)

5. Genetic and Immunologic Evaluation of Children With Inborn Errors of Immunity and Severe or Critical Covid-19, Journal of Allergy and Clinical Immunology (2022)

6. Safety and Immunogenicity of Corenapcin, a Sars-Cov-2 Mrna Vaccine, As a Fourth Heterologous Booster in Healthy Iranian Adults: A Double-Blind, Randomized, Placebo-Controlled, Phase 1 Clinical Trial With a Six-Month Follow-Up, International Immunopharmacology (2024)

7. Delving Into Revolutionary Sars-Cov-2 Vaccine Approaches: Molecular and Virological Examinations; Principles of Sars-Cov-2 Vaccine Platform; [Adentrandose En Enfoques Revolucionarios De Vacunas Sars-Cov-2: Examenes Moleculares Y Virologicos; Principios De La Plataforma De Vacunas Sars-Cov-2], Vacunas (2024)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (3)

Nasim Khajavirad (1)

Style	Citing Format
MLA	Zuo F, et al.. "Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant." Nature Communications, vol. 13, no. 1, 2022, pp. -.
APA	Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, De Camposmata L, Wan H, Schubert M, Cassaniti I, Wang Y, Sammartino JC, Sun R, Vlachiotis S, Bergami F, Kumagaibraesch M, Andrell J, Zhang Z, Xue Y, Wenzel EV, ... Panhammarstrom Q (2022). Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant. Nature Communications, 13(1), -.
Chicago	Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, De Camposmata L, Wan H, et al.. "Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant." Nature Communications 13, no. 1 (2022): -.
Harvard	Zuo F et al. (2022) 'Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant', Nature Communications, 13(1), pp. -.
Vancouver	Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, De Camposmata L, et al.. Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant. Nature Communications. 2022;13(1):-.
BibTex	@article{ author = {Zuo F and Abolhassani H and Du L and Piralla A and Bertoglio F and De Camposmata L and Wan H and Schubert M and Cassaniti I and Wang Y and Sammartino JC and Sun R and Vlachiotis S and Bergami F and Kumagaibraesch M and Andrell J and Zhang Z and Xue Y and Wenzel EV and Calzolai L and Varani L and Rezaei N and Chavoshzadeh Z and Baldanti F and Hust M and Hammarstrom L and Marcotte H and Panhammarstrom Q}, title = {Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant}, journal = {Nature Communications}, volume = {13}, number = {1}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Zuo F AU - Abolhassani H AU - Du L AU - Piralla A AU - Bertoglio F AU - De Camposmata L AU - Wan H AU - Schubert M AU - Cassaniti I AU - Wang Y AU - Sammartino JC AU - Sun R AU - Vlachiotis S AU - Bergami F AU - Kumagaibraesch M AU - Andrell J AU - Zhang Z AU - Xue Y AU - Wenzel EV AU - Calzolai L AU - Varani L AU - Rezaei N AU - Chavoshzadeh Z AU - Baldanti F AU - Hust M AU - Hammarstrom L AU - Marcotte H AU - Panhammarstrom Q TI - Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant JO - Nature Communications VL - 13 IS - 1 SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract